Global Interventional Oncology Market Size Study, By Technique (Ablation Therapies, Embolization Therapies), By Procedure (Tumor Ablation, Tumor Biopsy), By Application (Liver Cancer, Lung Cancer, Breast Cancer, Others), By End-use (Hospitals, Specialty C

The global interventional oncology market is valued at USD 2.53 billion in 2023 and is projected to grow at a CAGR of 9% from 2024 to 2032. Interventional oncology is an emerging field in cancer treatment, utilizing minimally invasive techniques such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), microwave ablation (MWA), and cryoablation. These advanced procedures are gaining prominence as they offer higher precision, reduced patient trauma, and quicker recovery times compared to conventional cancer treatments like surgery, chemotherapy, and radiation therapy.

The market's rapid expansion is fueled by the rising prevalence of cancer, advancements in image-guided procedures, and growing investments in minimally invasive oncology treatments. According to the World Health Organization (WHO), cancer was responsible for 10 million deaths in 2020, making it the second leading cause of mortality worldwide. The increasing burden of cancer worldwide has prompted healthcare providers and companies to develop innovative, effective, and less invasive therapeutic solutions.

The integration of AI, robotics, and real-time imaging technologies in interventional oncology is further enhancing procedural efficiency and patient outcomes. Companies such as Medtronic, Boston Scientific, and Terumo Corporation are investing heavily in R&D for advanced tumor-targeting and ablation solutions. Additionally, government and private funding initiatives are playing a pivotal role in accelerating market growth. For example, Royal Philips, along with its IMAGIO consortium, received a USD 25.97 million grant to support research on minimally invasive cancer treatments. Such investments are expected to drive the adoption of interventional oncology solutions worldwide.

Regional Insights- The North American market dominates the interventional oncology sector, accounting for 37.34% of the global revenue in 2023, driven by the presence of leading medical device companies, high healthcare expenditures, and favorable regulatory policies. The U.S. is witnessing substantial market growth due to the increasing prevalence of hepatocellular carcinoma (HCC) and lung cancer, along with strategic collaborations between research institutions and industry leaders.

In Europe, rising cancer prevalence and a growing emphasis on minimally invasive treatments are propelling market growth. According to the European Commission, 2.7 million people were diagnosed with cancer in 2022, a 2.3% increase from 2020. Additionally, government-backed funding programs and healthcare initiatives are fostering advancements in interventional oncology.

The Asia Pacific region is expected to witness the fastest CAGR of 11.55% from 2024 to 2032, attributed to high cancer incidence rates, expanding healthcare infrastructure, and increasing government initiatives. Countries like China, India, and Japan are experiencing a surge in oncology-focused investments and clinical trials, making the region a hotspot for market expansion and innovation.

Major Market Players Included in this Report:
• Medtronic plc
• Boston Scientific Corporation
• Johnson & Johnson (Ethicon)
• Baxter International Inc.
• Cook Medical
• C.R. Bard Inc. (Acquired by BD)
• AngioDynamics Inc.
• Stryker Corporation
• B. Braun Melsungen AG
• Terumo Corporation
• Siemens Healthineers
• GE Healthcare

The Detailed Segments and Sub-Segments of the Market are Explained Below:

By Technique:
• Ablation Therapies
Radiofrequency Ablation (RFA)
Microwave Ablation (MWA)
Cryoablation
Laser Ablation
Irreversible Electroporation (IRE)
• Embolization Therapies
Transarterial Chemoembolization (TACE)
Transarterial Radioembolization (TARE)
• Biopsy Techniques
Core Needle Biopsy
Fine Needle Aspiration (FNA)
• Targeted Therapy Delivery Systems
Drug-Eluting Beads
Radioembolization
Drug-Eluting Stents
Injectable Hydrogels and Nanoparticles
• Image-Guided Procedures
Ultrasound Guidance
CT Scan Guidance
MRI Guidance
Fluoroscopy Guidance

By Procedure:
• Tumor Ablation
• Tumor Biopsy
• Vascular Interventions
• Palliative Care

By Application:
• Liver Cancer
• Lung Cancer
• Kidney Cancer
• Prostate Cancer
• Breast Cancer
• Other Cancers

By End-Use:
• Hospitals
• Specialty Clinics
• Others

By Region:
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Italy
Spain
Denmark
Sweden
Norway
• Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
• Latin America
Brazil
Argentina
• Middle East & Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years (2022-2032).
• Annualized revenue and regional-level analysis for each market segment.
• Detailed geographical landscape with country-level analysis of major regions.
• Competitive landscape with market share insights from leading players.
• Analysis of key business strategies and recommendations for future market positioning.
• Competitive structure evaluation with SWOT analysis of major companies.
• Demand-side and supply-side assessment of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.